Seeking Alpha

GPRO
Gen-Probe Incorporated

5/26/2012, 8:47 AM ET
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
GPRO Market Currents more »
  • May 14 Hologic (HOLX +1.6%) ticks higher after JPMorgan ups the shares to Overweight. The firm says the upgrade was made to reflect compelling risk/reward and synergies from the Gen-Probe (GPRO) deal. Its price target is also raised to $22 from $20.
    Comment!
    [Healthcare, On the Move]
GPRO in Focus more »
GPRO Instablog posts more »
  • Biotech Correction Called Back in May & June 2011: Were You Paying Attention?
    Thu, Aug 4, 2011 • Justin M. Hall • Comment!
  • GAME PLAN: Playing Biotech in Front of Q2 Results
    Tue, Jul 12, 2011 • Justin M. Hall • Comment!
  • Biotech Stocks Overextended, Selling Will Resume Eventually => Rx Investors.com
    Mon, Jul 4, 2011 • Justin M. Hall • 2 Comments
  • Biotech Correction Isn't Done Yet [+earnings calendar] => Rx Investors.com
    Fri, Jun 24, 2011 • Justin M. Hall • Comment!
  • TOP 15 STOCKS TO WATCH THIS WEEK- AAPL, BRK-A, BRK-B, BJ, C, F, GM, GPRO, IP, KND, N, NRTLQ, ONTY, SPPI, YRCW
    Mon, May 2, 2011 • Amarendra Bhushan • Comment!
Write a post on GPRO
GPRO StockTalks
GPRO vs. ETF Alternatives
Company Description

Gen-Probe Incorporated (NASDAQ: GPRO) is a global leader in the development, manufacture and marketing of rapid, accurate and cost-effective nucleic acid tests, or NATs, used primarily to diagnose human diseases and screen donated human blood. NATs are designed to detect diseases more rapidly... More

Sector: Services
Industry: Research Services
Country: United States